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Abstract
Background: Cardiovascular disease (CVD) is the most common cause of mortality in pediatric chronic kidney
disease (CKD) patients. Left ventricular (LV) hypertrophy (LVH) is associated with LV diastolic dysfunction (LVDD)
development and is used as an early marker of CVD in pediatric CKD. This study aimed to assess the prevalence
and risk factors of LVDD and the association between LVH and LVDD in Korean pediatric CKD patients.
Methods: Data were collected using the baseline data of the Korean cohort study for outcome in patients with
pediatric chronic kidney disease, a nationwide, 10-year, prospective, observational cohort study of pediatric CKD. A
total of 244 patients were included in the final analysis. Two-dimensional echocardiography and tissue Doppler
images were used to evaluate LVH and LVDD. LVH was defined as an LV mass index (LVMI) ≥38 g/m2.7 and LV-wall
thickness z-score > 1.64. LVDD was defined as a mitral peak velocity of early filling to early diastolic mitral annular
velocity (E/E’) > 14. Univariate and multivariate logistic regression analyses were performed to evaluate risk factors of
LVDD.
Results: In this study, the male-to-female ratio was 2.2 (168:76) and median age was 11.2 years. The average
estimated glomerular filtration rate was 57.4 ml/min/1.73 m2, and no patients received renal replacement therapy.
The mean value of LVMI and E/E’ was 37.0 g/m2.7 and 7.4, respectively. The prevalence of LVH was 40.1 and 17.4%
by LVMI ≥38 g/m2.7 and LV-wall thickness z-score, respectively. The prevalence of LVDD was 4.5%, and patients with
LVH showed greater risk of LVDD (odds ratio 7.3, p = 0.012). In the univariate analysis, young age, low hemoglobin
level, higher LVMI, and higher LV-wall thickness z-score were associated with LVDD. In the multivariate analysis,
young age, low hemoglobin level, and higher LV-wall thickness z-score were independently associated with LVDD.
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Conclusion: This study shows that LVH patients have a greater risk of LVDD and that anemia is the only modifiable
risk factor for LVDD in Korean pediatric CKD patients.
Keywords: Chronic kidney disease, Left ventricular diastolic dysfunction, Children
Background
Chronic kidney disease (CKD) is an increasing public
health issue, and the prevalence of CKD in adults is esti-
mated to be 13.4% worldwide [1]. The prevalence of
pediatric CKD is 15–74.7 patients per 1 million children
and increased significantly until the first decade of the
twenty-first century when treatment and survival im-
proved [2]. Life expectancy is lower in pediatric CKD pa-
tients than in the healthy general population, and
cardiovascular disease (CVD) is a leading cause of mor-
tality accounting for 25–50% of death in pediatric CKD
[3–6]. Previous studies, including the Chronic Kidney
Disease in Children (CKiD) study cohort in the USA and
the Effect of Strict Blood Pressure Control and ACE In-
hibition on the Progression of CRI in PEdiatric Patients
(ESCAPE) and the Cardiovascular Phenotypes in Chil-
dren with CKD (4C) studies in Europe, have shown that
early alterations in cardiovascular structure and function
occur even before the need for renal replacement ther-
apy [7–9].
In CKD patients, left ventricular (LV) geometry and
diastolic function are changed at early stages while sys-
tolic functions are preserved until the late stage. These
changes are represented as LV hypertrophy (LVH) and
diastolic dysfunction (LVDD) by echocardiography and
used as an early marker of CVD [9, 10]. However, there
is no gold standard method for defining LVH and LVDD
in children. In several CKD studies, LV mass index
(LVMI) by height2.7 (m2.7) and the LV-wall thickness z-
score were used to define LVH with cut-off values of ≥
38 g/m2.7 and > 1.64 for LVMI and z-score, respectively
[11–13]. LVDD can be measured by the peak of early
diastolic flow velocities (E), peak of late diastolic flow
velocities (A) by conventional echocardiography, early
diastolic peak filling velocity (E’), and late diastolic peak
filling velocity (A’) by tissue Doppler echocardiography.
The ratio E to E’ is a reliable indicator of diastolic dys-
function and a value over 14 indicates LVDD in adults
[14–16]. However, there is no determined cut-off value
to define LVDD in pediatric CKD patients. This lack of
information makes it difficult to analyze the prevalence
and clinical characteristics of pediatric CKD patients
with LVDD.
The aim of this study is to detect the prevalence of
LVDD in Korean pediatric CKD and the clinical differ-
ence according to the presence of LVDD. In addition, as
there is no gold standard method for defining LVDD, we
are suggesting a cut-off value of E/E’ normalized to the
age-independent z-score to define LVDD in pediatric
CKD patients.
Methods
Study design and population
We used the baseline data of the KoreaN cohort study
for Outcome in patients With Pediatric Chronic Kidney
Disease (KNOW-Ped CKD), a nationwide, 10-year, pro-
spective, observational cohort study of pediatric CKD.
The design and methods of KNOW-Ped CKD are pub-
lished [17]. The study protocol was approved by the In-
stitutional Review Boards of participating clinical centers
in 2011. A total of 469 pediatric patients with CKD were
registered from the seven major pediatric nephrology
centers in Korea. The LVH and LVDD data from echo-
cardiography was available in 395 and 244 patients, re-
spectively. Finally, 244 pediatric CKD patients were
included in this study.
Ethical statement
All the data were obtained in accordance with the ethical
principles for medical research involving human subjects
established in the Declaration of Helsinki 1975 (revised
in 2000).
Clinical and laboratory measurements
Demographic data and laboratory values were obtained
from the web-based data management system, PhactaX
(version 1.0). Biochemical values were measured at the
hospital laboratories of participating centers. Estimated
glomerular filtration rate (eGFR) was calculated using
the modified Schwartz equation [18]. The CKD stage
was defined according to the Kidney Disease Improving
Global Outcome (KDIGO) criteria [19]. The biochemical
values were measured at each participating hospital
laboratory and additional serum and urine samples were
collected for the central laboratory (Lab genomics,
Korea). In the central laboratory, serum creatinine (Cr),
intact parathyroid hormone (iPHT), 25-OH vitamin D,
and 1,25-OH vitamin D levels were measured.
The hypertension was defined when systolic or diastolic
blood pressure was above age-, sex-, and height-specific 95th
percentile or when the patient was on anti-hypertensive
medication. Two-dimensional echocardiography and tissue
Doppler were performed by pediatric cardiologists at each
center to measure cardiac parameters according to the
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American Society of Echocardiography pediatric guidelines
[16]. The left ventricular mass index was measured from the
M-mode measurement of the interventricular septum (IVS),
LV inner dimension (LVID), and LV posterior wall thickness
(LVPW) using the Devereux formula [20]. LVH was defined
in two ways using the LV mass in grams divided by the
height in meters to the 2.7th power ≥ 38 g/m2.7 (LVH 1) or a
height-specific normalized LV wall thickness z-score > 1.64
(LVH 2). Early diastolic velocity ratio (E/E’) was evaluated by
measuring early mitral valve ventricular filling velocity (E) in
conventional echocardiography and early diastolic annular
velocity (E’) in tissue Doppler echocardiography. The LVDD
was defined using an E/E′ > 14 by tissue Doppler imaging.
The E/E’ ratio was normalized to patient age by z-score cal-
culation using a published reference based on 325 healthy
children [21].
Statistical analysis
Statistical analysis was conducted by SPSS Version 25.
The continuous variables with normal distribution are
described as the mean ± standard deviation. The con-
tinuous variable with non-normal distribution are
expressed as mean ± standard deviation, or median value
with interquartile range, whichever describes the data
well. A Student’s t-test was used for normally distributed
numerical data and Mann–Whitney test was used for
non-normally distributed numerical data. Logistic re-
gression analysis was used to evaluate the odds ratio
(OR) and confidence interval (CI) for the presence of
LVDD associated with each variable. Variable with P <
0.1 from univariate analysis were entered in multivariate
regression analysis. A chi-squared test and Fisher’s exact
test were used for categorical data. The Youden’s index
analyzed by empirical method was used to determine the
cut-off value for LVDD by E/E’ z-score as it showed nor-
mal distribution.
Results
Participant baseline characteristics and prevalence of
LVDD
Demographic and clinical data for 244 patients are listed
in Table 1. The median age was 11.2 years old and males
was two times more prevalent than females in this cohort.
The mean eGFR value was 57.4 and half of the patients
were CKD stage III or IV. The patients showed a low z-
score of body weight, height, and body mass index (BMI).
In 157 patients (71.4%) had hypertension at baseline. In
141 patients (58.3%) who received anti-hypertensive medi-
cations, 35 patients had a combination of antihypertensive
medications (2 medications, n = 28; 3 medications, n = 7).
Angiotensin-converting-enzyme inhibitors (ACE inhibi-
tors) or angiotensin II receptor blockers (ARBs) were
taken in 137 (97.2%) patients and other medications were
taken in 4 patients (2.8%). LVMI data showed a mean
value of 37.0 g/m2.7 (LVMI/height2.7) and mean LV wall
thickness z-score of -2.9. The prevalence of LVH was
40.1% based on LVMI ≥ 38 g/m2.7 and 17.4% based on LV
wall thickness z-score > 1.68. Measured for LVDD evalu-
ation, the mean value of E/E’ ratio and E/E’ z-score was
7.4 and 1.3, respectively. The prevalence of LVDD was
4.5% based on E/E’ ratio > 14.
Calculation of optimal E/E’ ratio value for LVDD
To estimate the optimal E/E’ ratio reflecting LVDD in
children, we normalized the E/E’ ratio to patient age by
calculating the z-score based on published reference data
Table 1 Demographic and clinical data in cohort patients
Variables Entire patient
(n = 244)
Age (years) 11.2 (0.3–17.9)
Sex (Male/Female) 168/76
Body weight, z-score − 0.8 ± 1.8
Height, z-score − 0.9 ± 1.6
Body mass index, z-score −0.3 ± 1.4






Hypertension (n = 220) 157 (71.4)
Systolic blood pressure > 95 percentile (n = 204) 27 (13.2)
Diastolic blood pressure > 95 percentile (n = 204) 47 (23.0)
Overall blood pressure > 95 percentile (n = 204) 58 (28.4)




angiotensin II receptor blockers
137 (97.2)
Other medications 4 (2.8)
Laboratory data
Hemoglobin (g/dL) 12.4 ± 1.8
Estimated glomerular filtration rate
(ml/min/1.73 m2)
57.4 ± 38.2
Serum Ca (mg/dL) 9.5 ± 0.7
Serum P (mg/dL) 4.8 ± 0.8
Intact parathyroid hormone (pg/mL) 55.2 (5.8–1244.0)
Echocardiography
Left ventricular mass index (g/m2.7) 37.0 ± 13.0
Patients with left ventricular hypertrophy 97/242 (40.1)
Early diastolic velocity ratio (E/E’) 7.4 ± 3.0
Data are presented as the mean ± standard deviation, as the median with the
full range given in the parentheses, or as the number of patients with the
percentage given in parentheses
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from a cohort of 325 healthy children. Based on the def-
inition of LVDD with a measured E/E’ ratio above 14,
the E/E’ z-score optimal cut-off value was estimated by
Youden’s index to be 3.415 for predicting LVDD (C-stat-
istic = 0.963, sensitivity/specificity = 0.909/0.9313) (Fig. 1).
According to newly suggested E/E’ z-score cut-off value,
26 patients (10.7%) were classified as LVDD.
Clinical difference between patients with and without
LVDD
The comparisons between groups with or without
LVDD based on an E/E’ ratio > 14 is shown in Table 2.
There was no gender difference between groups and
more than half of CKD patients with LVDD were early
stage CKD (stage 1 and 2). The patients with LVDD
were younger (p = 0.037) than those without LVDD. The
values of LVMI and LV wall thickness z-score were
higher in CKD patients with LVDD (p = 0.002 and p =
0.008) compared with those without LVDD. There were
no differences in the levels of serum calcium, serum
phosphorus, and calcium x phosphorus product and
hypertension prevalence between groups.
Contributing factors for LVDD
LVDD, defined by measured value of E/E’ > 14, was asso-
ciated with younger age (p = 0.046), low hemoglobin
level (p = 0.018), increased LVMI/height2.7 (p = 0.006),
and increased LV-wall thickness z-sore (p = 0.011) by
univariate logistic regression. However, there was no as-
sociation between LVDD and hypertension. Even though
the prevalence of LVH was not exact according to the
different methods of definition, patients with LVDD
showed greater risk of LVH (LVH1: OR 7.3, p = 0.012;
and LVH2: OR 4.4, p =0.020).
As LVM is indexed by two methods in this study, we
analyzed the contributing factors for LVDD with each
method. When LVM was indexed by height2.7, low
hemoglobin level was independently associated with
LVDD by multivariable logistic regression (Table 3).
When LVM was indexed as LV-wall thickness z-score,
low hemoglobin level, young age, and LV wall thickness
z-score were independently associated with LVDD by
multivariable logistic regression (Table 4).
LVDD, defined by newly suggested E/E’ z-score >
3.415, was associated with increased LV-wall thickness
z-sore (OR 1.2, p = 0.002), presence of LVH2 (OR 4.7,
p = 0.0005), and not with age by univariate logistic ana-
lysis. Only presence of LVH2 showed association with
LVDD in multivariable logistic regression (OR 4.0, p =
0.0038) (Table 5).
Discussion
The LVH is a well-known LV geometry change in
pediatric CKD patients, which progress as CKD stage
advance and showed association with hyperparathyroid-
ism, vitamin D deficiency, anemia, and hypertension in
previous studies [22, 23]. Previously, unlike systolic dys-
function presented in adult progressed CKD patients, in
pediatric CKD patients, the systolic function was pre-
sumed preserved [24]. However, further research re-
vealed that subclinical systolic dysfunction (abnormal
systolic walls mechanics with preserved LV chamber
function) exists in pediatric CKD patients [25]. Even
though the hypertension was thought to be the main
factor which affects the LVH progression in pediatric
CKD patient, it was often under and even untreated
[26]. In the study conducted by Matteucci et al. revealed
that strictly controlled blood pressure showed regression
of LVH and improvement of subclinical systolic function
in pediatric CKD patients expected to result in cardio-
vascular outcome improvement [27]. Also, in other stud-
ies, not only hypertension but also cardiac output
increment and nonhemodynamic factors showed an as-
sociation with the prevalence of LVH in pediatric CKD
patients [28, 29]. Therefore, like LVH, it is also crucial
to find modifiable factors associated with LVDD in CKD
patients to improve their cardiovascular outcomes by
improving LVDD. However, there is a lack of data re-
garding LVDD in pediatric CKD patients. The preva-
lence of LVDD in our study was 4.5%, which was lower
compared with previous studies [30]. The low prevalence
may be explained in some ways by the characteristics of
the enrolled patients and the different definitions of
LVDD. The previously reported prevalence of LVDD in
pediatric dialysis CKD patients, based on an E/E’ ratio
Fig. 1 Receiver operating characteristic curve to estimate the
optimal E/E’ z-score cut-off value
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above the maximum value (max E/E’ ratio in healthy
control was 11.9) of healthy age- and gender-matched
controls, was 29%. As dialysis CKD patients had worse
LVDD than pre-dialysis CKD patients, the prevalence of
LVDD in overall CKD may be much lower [30]. The in-
crement of LVH prevalence according to progressive
CKD stage in children is also well known [31]. Our
patients were in pre-dialysis condition, and the evalu-
ation of the secular trend of LVDD prevalence is
necessary.
The cut-off value of the E/E’ ratio to define LVDD
may have influenced the prevalence in our study. There
were several studies in which CKD children have worse
LVDD than healthy children, and LVDD worsened as
Table 2 Clinical differences in pediatric CKD patients with and without left ventricular diastolic dysfunction
Variable Patients with left ventricular
diastolic dysfunction (n = 11)
Patients without left ventricular
diastolic dysfunction (n = 233)
P value
Age, median (full range) 7.6 (0.5–13.0) 11.4 (0.3–17.9) 0.037
Male/Female 6/5 162/71 0.325
Chronic kidney disease stage
I 4 (36.4) 41 (17.6)
II 3 (27.3) 44 (18.9)
III 2 (18.2) 83 (35.6)
IV 2 (18.2) 43 (18.5)
V – 22 (9.4)
Height Z-score −1.2 ± 1.0 −0.8 ± 1.6 0.445
Weight Z-score −1.1 ± 1.1 −0.8 ± 1.8 0.332
Body mass index Z-score −0.3 ± 1.2 −0.3 ± 1.4 0.861
Estimated glomerular filtration rate (ml/min/1.73 m2) 76.7 ± 46.0 56.5 ± 37.7 0.117
Hypertension 6 (66.7) 151 (71.6) 0.718
Hemoglobin (g/dL) 11.1 ± 1.8 12.4 ± 1.8 0.015
Transferrin Saturation (%) 27.6 ± 21.1 27.8 ± 13.0 0.589
Serum albumin (g/dL) 4.1 ± 0.4 4.1 ± 0.6 0.353
Serum Ca (mg/dL) 9.2 ± 0.5 9.5 ± 0.7 0.062
Serum P (mg/dL) 4.8 ± 0.5 4.8 ± 0.9 0.944
Ca x P (mg2/dL2) 43.9 ± 5.4 45.5 ± 8.5 0.456
Serum tCO2 (mmol/L) 23.3 ± 3.8 22.5 ± 3.5 0.715
Total cholesterol (mg/dL) 154.3 ± 20.7 184.5 ± 70.4 0.054
Serum low-density lipoprotein cholesterol (mg/dL) 95.0 ± 17.2 106.1 ± 63.5 0.888
Serum high-density lipoprotein cholesterol (mg/dL) 46.3 ± 11.9 54.4 ± 15.0 0.077
Serum triglyceride (mg/dL) 108.6 ± 37.5 153.5 ± 158.9 0.347
Intact parathyroid hormone (pg/mL) 49.8 (17.1–243.0) 55.3 (5.8–1244.0) 0.926
25 (OH) vitamin D3 (ng/mL) 26.0 ± 17.3 21.1 ± 9.2 0.452
Tubular reabsorption of phosphate (%) 90.5 ± 8.3 77.6 ± 13.7 0.009
Left ventricular mass index (g/m2.7) 48.8 ± 14.9 36.5 ± 12.7 0.002
left ventricular wall thickness z-score 1.4 ± 3.7 −3.1 ± 6.3 0.008
Data are presented as the mean ± standard deviation, as the median with the full range given in the parentheses, or as the number of patients with the
percentage given in parentheses
Table 3 Associated factors of left ventricular diastolic dysfunction with the definition of LVH1
Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Age 0.882 (0.78–0.998) 0.046 – –
Hemoglobin 0.67 (0.481–0.933) 0.018 0.566 (0.373–0.859) 0.007
LVH1 Left ventricular hypertrophy defined by left ventricular mass in grams divided by height in meter to the 2.7th power ≥ 38 g/m2.7; OR Odds ratio, CI
Confidence interval
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CKD progressed [30, 32]. However, the absence of a
consensus standard method for defining LVDD affected
the lack of interpretation of LVDD clinical significance
in pediatric CKD patients. Children are in the process of
growth and which impacts echocardiography parameters
as the heart grows [21]. Therefore, the definition of LVH
in pediatric patients are indexed by multiple ways in-
cluding body size, age-specific reference, and the LVM
percentile according to height [11, 12, 33]. Like LVH,
the LVDD definition needs to be normalized or indexed
in pediatric patients. To establish a reference value of
Doppler tissue imaging in children, Eiden et al. gathered
echocardiography parameters in 325 healthy children
(age range: 1 day to 18 years) in the USA. This study
found a significant association between E/E’ and age in
healthy children [21]. Recently reported data from the
4C study showed impaired systolic and diastolic function
in pediatric CKD patients by using normalized echocar-
diographic parameters to age-independent z-score ac-
cording to the reference data mentioned above [34].
Likewise, we normalized the E/E’ ratio to age by using
the reference value reported by Eiden et al. As we used
an E/E’ ratio > 14 based on adult data to define LVDD,
we attempted to find an optimal E/E’ z-score cut-off
value to define LVDD in pediatric CKD patients by You-
den’s index [15, 21, 35]. The estimated cut-off value of
the E/E’ z-score was 3.415 in this study. Further studies
are needed to validate the impact of LVDD defined by
an E/E’ z-score > 3.415 on long term outcomes in
pediatric CKD including CVD events. Additionally, since
pediatric CKD patients are accompanied by inadequate
growth problem, age-independent E/E’ z-score might
not be the best way to normalize LVDD in pediatric
CKD patients. Like LVH defining methodologies, body
size, age-specific indexed E/E’ ratio should be considered
in the future.
This study describes the clinical differences associated
with the presence of LVDD in pediatric CKD patients.
In previous studies, the E/E’ ratio in pediatric CKD
showed an association with young age, serum phos-
phorus level, calcium x phosphorous product, LVMI,
and anemia but not with hypertension [10, 30, 32]. Un-
like the adult population showing strong relation be-
tween LVDD and blood pressure, E/E’ ratio in children
showed association only to BMI, waist circumference,
obesity, and not to hypertension, based on a large sam-
ple study of non-CKD children [36, 37]. The LVDD in
this study was associated with young age, low
hemoglobin level, and LV wall thickness z-score, not
with hypertension, which was similar to previous re-
ports. Additionally, as LVDD develops more in dialysis
than non-dialysis CKD patients, volume overload might
be a more important factor in developing LVDD in
pediatric CKD patients than pressure overload [10]. As
LVDD defined by age-standardized E/E’ ratio showed no
association with age, previously known contributing fac-
tor of younger age to LVDD might be a result of paucity
of E/E’ reference value in pediatric population. Still,
further validation is required in optimal E/E’ Z-score
cut-off value. Among the revealed LVDD contributing
factors, only anemia is an adjustable factor in pediatric
CKD patients. Further, LVH needs to be close moni-
tored in LV wall thickness z-score. However, LVH
defined as an LVMI ≥ 38 g/m2.7 and LV wall thickness
z-score > 1.64 shows poor concordance and this discre-
pancy needs to be studied in future research [13].
This study has several limitations. First, echocardiog-
raphy was performed by pediatric cardiologists in each
center without central reading validation, which can
show poor concordance between examiners. Second, this
study only included data from baseline pre-dialysis CKD
patients. Although LVDD may exist in early CKD, it is
well known that LVDD worsens as CKD progresses, and
a longitudinal study is necessary to evaluate the overall
prevalence. Third, the normalized E/E’ z-score was based
on a reference from 325 healthy children in the USA.
This study includes Korean children, and ethnic differ-
ences may influence the results.
Table 4 Associated factors of left ventricular diastolic dysfunction with the definition of LVH2
Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Age 0.882 (0.78–0.998) 0.046 0.659 (0.509–0.853) 0.002
Hemoglobin 0.67 (0.481–0.933) 0.018 0.538 (0.318–0.912) 0.021
LV wall thickness z-score 1.197 (1.043–1.373) 0.011 1.537 (1.225–1.928) 0.000
LV Left ventricular, LVH2 height-specific normalized LV wall thickness z-score > 1.64, OR Odds ratio, CI Confidence interval
Table 5 Associated factors of left ventricular diastolic dysfunction define by E/E’ ratio z-score > 3.415 with the definition of LVH2
Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
LV wall thickness z-score 1.173 (1.060–1.298) 0.0020 – –
LVH2 4.714 (1.962–11.326) 0.0005 4.04 (1.57–10.4) 0.0038
LV Left ventricular, LVH2 height-specific normalized LV wall thickness z-score > 1.64, OR Odds ratio, CI Confidence interval
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Conclusion
This study showed a 4.5–10.7% prevalence of LVDD in
pre-dialysis CKD, which is associated with young age,
anemia, and LV-wall thickness z-score. Further, we sug-
gest an E/E’ z-score of 3.415 as optimal cut-off value to
define LVDD in pediatric CKD patients.
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